

Elisabetta Munzone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8794622/publications.pdf>

Version: 2024-02-01

124
papers

5,112
citations

147566

31
h-index

91712

69
g-index

127
all docs

127
docs citations

127
times ranked

6715
citing authors

#	ARTICLE	IF	CITATIONS
1	The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients. <i>Anti-Cancer Drugs</i> , 2022, 33, e628-e634.	0.7	4
2	Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. <i>Journal of Personalized Medicine</i> , 2022, 12, 72.	1.1	26
3	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 3.	2.3	33
4	Predicting Effective Adaptation to Breast Cancer to Help Women BOUNCE Back: Protocol for a Multicenter Clinical Pilot Study. <i>JMIR Research Protocols</i> , 2022, 11, e34564.	0.5	6
5	CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer. <i>Nature Communications</i> , 2022, 13, 2642.	5.8	15
6	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 443-452.	3.0	22
7	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor- α -positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , 2021, 27, 504-512.	3.2	5
8	Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. <i>Cancers</i> , 2021, 13, 583.	1.7	13
9	Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after treatment with endocrine therapy and CDK 4/6 inhibitors within randomized clinical trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 1059-1059.	0.8	0
10	Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2051-2061.	0.8	11
11	Ten-year outcome results of cT4 breast cancer after neoadjuvant treatment. <i>Journal of Surgical Oncology</i> , 2021, 124, 1242-1250.	0.8	5
12	Expert Discussion: Predictive Markers. <i>Breast Care</i> , 2021, 16, 1-6.	0.8	0
13	Management of breast cancer patients during the peak of the COVID 19 pandemic. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2694-2695.	0.5	1
14	Systematic review and meta-analysis of post-progression outcomes in ER+/HER2 α metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials. <i>ESMO Open</i> , 2021, 6, 100332.	2.0	16
15	Pegylated Liposomal Doxorubicin (Caelyx $\text{\textcircled{R}}$) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial. <i>Current Oncology</i> , 2021, 28, 5167-5178.	0.9	3
16	Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy. <i>Breast</i> , 2020, 53, 138-142.	0.9	9
17	Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 783-795.	1.1	3
18	Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. <i>Biomedicine Hub</i> , 2020, 5, 1-42.	0.4	15

#	ARTICLE	IF	CITATIONS
19	<p>Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives</p>. Breast Cancer: Targets and Therapy, 2020, Volume 12, 45-56.	1.0	15
20	155P Prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients. Annals of Oncology, 2020, 31, S72.	0.6	0
21	Abstract P2-14-18: Caelyx® as adjuvant treatment in early stage luminal B breast cancer: A feasibility phase II trial. , 2020, , .		0
22	Abstract PD8-04: Ultra-deep multigene profiling of matched primary and metastatic hormone receptor positive breast cancer patients relapsed after adjuvant endocrine treatment reveals novel aberrations in the estrogen receptor pathway. , 2020, , .		1
23	Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines. British Journal of Cancer, 2019, 121, 325-331.	2.9	25
24	Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. BMC Cancer, 2019, 19, 902.	1.1	6
25	Reply to Comments on: “Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp cooling system in early breast cancer patients treated with anthracyclines.” British Journal of Cancer, 2019, 121, 806-806.	2.9	7
26	<p>Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?</p>. OncoTargets and Therapy, 2019, Volume 12, 2989-2997.	1.0	23
27	Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. Journal of Clinical Oncology, 2019, 37, 386-395.	0.8	16
28	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 2019, 37, 559-569.	0.8	505
29	Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease. Breast, 2019, 48, S49-S52.	0.9	4
30	Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project. Advances in Therapy, 2019, 36, 381-406.	1.3	19
31	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical Reviews in Oncology/Hematology, 2019, 134, 39-45.	2.0	200
32	Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer. Clinical Breast Cancer, 2018, 18, 328-335.	1.1	13
33	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. Breast Cancer Research and Treatment, 2018, 170, 351-360.	1.1	5
34	Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial. Breast Care, 2018, 13, 177-181.	0.8	31
35	Optimal management of luminal breast cancer: how much endocrine therapy is long enough?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877743.	1.4	12
36	Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?. Expert Review of Anticancer Therapy, 2018, 18, 805-814.	1.1	1

#	ARTICLE	IF	CITATIONS
37	The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of indolent-stage IV disease (Stage IV indolent).. Journal of Clinical Oncology, 2018, 36, 1019-1019.	0.8	3
38	Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the SOLE trial.. Journal of Clinical Oncology, 2018, 36, 517-517.	0.8	1
39	Metronomics in the neoadjuvant and adjuvant treatment of breast cancer. Cancer Letters, 2017, 400, 259-266.	3.2	14
40	Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial. Cancer Letters, 2017, 400, 276-281.	3.2	34
41	Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Annals of Oncology, 2017, 28, 305-312.	0.6	25
42	Mutations targeting the coagulation pathway are enriched in brain metastases. Scientific Reports, 2017, 7, 6573.	1.6	10
43	Anti-HER2 Therapies in the Adjuvant and Advanced Disease Settings. , 2017, , 577-591.		0
44	Long-term responders to trastuzumab monotherapy in the first-line metastatic setting: characteristics and survival data (SAKK 22/99 Trial). Annals of Oncology, 2017, 28, v99.	0.6	0
45	Surgical Resection Margins after Breast-Conserving Surgery: Senonetwork Recommendations. Tumori, 2016, 102, 284-289.	0.6	14
46	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Research and Treatment, 2016, 158, 323-331.	1.1	100
47	Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis. International Journal of Cancer, 2016, 139, 212-219.	2.3	63
48	Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer. Future Oncology, 2016, 12, 2001-2008.	1.1	6
49	Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development. Future Oncology, 2016, 12, 373-387.	1.1	43
50	1876 A phase II study of metronomic oral chemotherapy for metastatic breast cancer patients: Safety and efficacy results of vinorelbine, cyclophosphamide plus capecitabine (VEX) combination. European Journal of Cancer, 2015, 51, S291-S292.	1.3	7
51	Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma. Melanoma Research, 2015, 25, 239-245.	0.6	23
52	Development and psychometric testing of a breast cancer patient-profiling questionnaire. Breast Cancer: Targets and Therapy, 2015, 7, 133.	1.0	18
53	Clinical overview of metronomic chemotherapy in breast cancer. Nature Reviews Clinical Oncology, 2015, 12, 631-644.	12.5	109
54	Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. Annals of Oncology, 2015, 26, 2442-2449.	0.6	8

#	ARTICLE	IF	CITATIONS
55	Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer. <i>Drugs</i> , 2015, 75, 1311-1321.	4.9	5
56	Picking the optimal endocrine adjuvant treatment for pre-menopausal women. <i>Breast</i> , 2015, 24, S11-S14.	0.9	6
57	Outcome of Immediate Breast Reconstruction in Patients With Nonendocrine-Responsive Breast Cancer: A Monoinstitutional Case-Control Study. <i>Clinical Breast Cancer</i> , 2015, 15, e237-e241.	1.1	13
58	Abstract P4-15-11: Advanced HER2 positive breast cancer treated with trastuzumab: Is combination with chemotherapy always needed? Randomized phase III trial SAKK 22/99. , 2015, , .		0
59	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 463.	0.6	26
60	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 426.	0.6	8
61	The role of maintenance strategies in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 152-156.	0.3	1
62	Outcome of Male Breast Cancer: A Matched Single-Institution Series. <i>Clinical Breast Cancer</i> , 2014, 14, 371-377.	1.1	32
63	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 406-414.	5.1	703
64	A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. <i>European Journal of Cancer</i> , 2014, 50, 277-289.	1.3	212
65	Metronomic therapy and breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2014, 40, 942-950.	3.4	44
66	Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 573-582.	1.1	9
67	Metronomic Chemotherapy in Breast Cancers. , 2014, , 93-110.		2
68	Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer?. <i>Anticancer Research</i> , 2014, 34, 6677-83.	0.5	11
69	ecancermedalscience. <i>Ecancermedalscience</i> , 2013, 7, 309.	0.6	1
70	Extended adjuvant chemotherapy in endocrine non-responsive disease. <i>Breast</i> , 2013, 22, S161-S164.	0.9	4
71	Therapeutic effect of β -blockers in triple-negative breast cancer postmenopausal women. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 567-575.	1.1	113
72	Tailoring Adjuvant Treatments for the Individual Patient with Luminal Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 703-714.	0.9	5

#	ARTICLE	IF	CITATIONS
73	Role of breast surgery in T1-3 breast cancer patients with synchronous bone metastases. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 303-310.	1.1	6
74	Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. <i>Acta Oncologica</i> , 2013, 52, 1649-1656.	0.8	56
75	Prognostic effect of beta blockers (BB) in triple-negative breast cancer (TNBC) patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1061-1061.	0.8	8
76	ALGA: A cancer patient profiling tool to improve physician-patient communicationâ€”An analysis in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9582-9582.	0.8	0
77	Outcome and clinicalâ€”biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases. <i>Annals of Oncology</i> , 2012, 23, 2884-2890.	0.6	2
78	CMF revisited in the 21st century. <i>Annals of Oncology</i> , 2012, 23, 305-311.	0.6	22
79	Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?. <i>Anti-Cancer Drugs</i> , 2012, 23, 1089-1098.	0.7	6
80	Prognostic Value of Circulating Tumor Cells According to Immunohistochemically Defined Molecular Subtypes in Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2012, 12, 340-346.	1.1	46
81	Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report. <i>Breast Journal</i> , 2012, 18, 470-474.	0.4	25
82	Targeting the subtypes of breast cancer: rethinking investigational drugs. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 191-204.	1.9	3
83	Prognostic value of circulating tumor cells in primary and metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 203-214.	1.1	16
84	Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 277-282.	1.1	61
85	Role of breast surgery in T1-T3 breast cancer patients with synchronous bone metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1115-1115.	0.8	1
86	A meta-analysis of receptor status discordance between primary breast cancer and metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 546-546.	0.8	1
87	A prognostic model for predicting breast cancer (BC)-related survival in operable triple-negative (TN) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1049-1049.	0.8	0
88	Should liver metastases of breast cancer be biopsied to improve treatment choice?. <i>Annals of Oncology</i> , 2011, 22, 2227-2233.	0.6	103
89	First-line therapy with metronomic capecitabine (mC) plus docetaxel (D) followed by mC as maintenance for patients with HER2-negative metastatic breast cancer (MBC): Preliminary analysis of a monocentric phase II trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, e11547-e11547.	0.8	1
90	Prognostic significance of Ki-67 in node-negative (pN0), triple-negative (TN) breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 1056-1056.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 211-217.	1.1	70
92	Changes of HER2 Status in Circulating Tumor Cells Compared With the Primary Tumor During Treatment for Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 392-397.	1.1	96
93	Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report. <i>Breast</i> , 2010, 19, 33-37.	0.9	25
94	Dacarbazine (DTIC) plus bevacizumab (B) combination therapy in chemotherapy (CTh)-naïve advanced melanoma (MM) patients (pts): A phase II study.. <i>Journal of Clinical Oncology</i> , 2010, 28, 8536-8536.	0.8	1
95	Clinical Relevance of <i>HER2</i> Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5693-5699.	0.8	235
96	A phase II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. <i>British Journal of Cancer</i> , 2009, 100, 28-36.	2.9	76
97	Circulating endothelial cells (CECs), progenitors (CEPs), and circulating tumor cells (CTCs) for prediction of response in patients with advanced breast cancer (ABC) receiving metronomic oral vinorelbine (oV): Preliminary results. <i>Journal of Clinical Oncology</i> , 2009, 27, e14572-e14572.	0.8	0
98	Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. <i>Annals of Oncology</i> , 2008, 19, 891-897.	0.6	144
99	Acquisition of HER2/neu over-expression on circulating tumor cells (CTCs) in patients (pts) with advanced breast cancer (ABC) during chemotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 11017-11017.	0.8	4
100	Waiting room related symptoms: Patients' experiences in an outpatient clinic of a cancer center. <i>Journal of Clinical Oncology</i> , 2008, 26, 20614-20614.	0.8	0
101	Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination. <i>Annals of Oncology</i> , 2007, 18, 1969-1975.	0.6	14
102	A phase II trial of dacarbazine (DTIC) and bevacizumab in patients with metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 8579-8579.	0.8	6
103	Breast cancer vaccines: a clinical reality or fairy tale?. <i>Annals of Oncology</i> , 2006, 17, 750-762.	0.6	76
104	Capecitabine/Vinorelbine: An Effective and Well-Tolerated Regimen for Women with Pretreated Advanced-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2006, 6, 518-524.	1.1	25
105	Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2006, 17, 322-329.	0.6	40
106	Pegylated liposomal doxorubicin (PLA) at a metronomic schedule for patients with advanced breast cancer (ABC). <i>Journal of Clinical Oncology</i> , 2006, 24, 10571-10571.	0.8	0
107	Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab. <i>Breast</i> , 2005, 14, 380-383.	0.9	14
108	Systemic Effects of Surgery: Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF- β 2) in Patients with Breast Cancer Who Underwent Limited or Extended Surgery. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 35-40.	1.1	59

#	ARTICLE	IF	CITATIONS
109	Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer. <i>Annals of Oncology</i> , 2005, 16, 1609-1617.	0.6	4
110	Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. <i>Breast Cancer Research</i> , 2005, 8, R4.	2.2	67
111	Oral vinorelbine in combination with capecitabine: phase I study in patients with metastatic breast cancer. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 134.	2.2	3
112	Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study. <i>Annals of Oncology</i> , 2001, 12, 95-100.	0.6	17
113	Unexpected Right Phrenic Nerve Injury During 5-Fluorouracil Continuous Infusion Plus Cisplatin and Vinorelbine in Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2000, 92, 755-755.	3.0	8
114	Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF regimen). <i>Annals of Oncology</i> , 1999, 10, 1394-1395.	0.6	4
115	Primary chemotherapy in operable breast cancer with favorable prognostic factors: A pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). <i>Annals of Oncology</i> , 1999, 10, 993-996.	0.6	20
116	Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 701-708.	3.3	45
117	Pharmacokinetics of anticancer agents in patients with impaired liver function. <i>European Journal of Cancer</i> , 1998, 34, 33-46.	1.3	110
118	High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: Is it feasible?. <i>Annals of Oncology</i> , 1998, 9, 917-919.	0.6	35
119	Synergistic Activity of Oxaliplatin and 5-Fluorouracil in Patients With Metastatic Colorectal Cancer With Progressive Disease While on or After 5-Fluorouracil. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 279-283.	0.6	39
120	Visual evoked potentials findings in course of paclitaxel doxorubicin combination chemotherapy. <i>Journal of Neuro-Oncology</i> , 1995, 25, 221-225.	1.4	10
121	Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.. <i>Journal of Clinical Oncology</i> , 1995, 13, 2688-2699.	0.8	515
122	Paclitaxel in Metastatic Breast Cancer:-a Trial of Two Doses by a 3-Hour Infusion in Patients With Dith Disease Recurrence After Prior Therapy With Anthracyclines. <i>Journal of the National Cancer Institute</i> , 1995, 87, 1169-1175.	3.0	136
123	Optic Nerve Disturbances: a New Form of Paclitaxel Neurotoxicity. <i>Journal of the National Cancer Institute</i> , 1994, 86, 1099-1101.	3.0	89
124	Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. <i>Seminars in Oncology</i> , 1994, 21, 29-33.	0.8	8